Publications by authors named "S Dalac"

Claim this Profile
E
Effectiveness, safety and reasons for discontinuation of sonidegib for patients with locally advanced basal cell carcinoma: A real-word evidence analysis from the French national registry CARADERM.
Nicole Basset-Seguin, Mourad Djermane, Florian Herms, Sophie Dalac, Olivier Dereure

J Eur Acad Dermatol Venereol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased risk of cutaneous squamous cell carcinomas in patients with Sézary syndrome: A nationwide multicenter retrospective study.
Louise Guillon, Caroline Ram-Wolff, Serge Boulinguez, Marie Beylot-Barry, Michel D'Incan, Sophie Dalac

J Am Acad Dermatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world setting.
Karine Billard, Laurent Mortier, Olivier Dereure, Sophie Dalac, Henri Montaudié

Br J Dermatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort.
Camille Macaire, Wendy Lefevre, Sophie Dalac, Henri Montaudié, Delphine Legoupil

Melanoma Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When to stop immunotherapy for advanced melanoma: the emulated target trials.
Mathilde Amiot, Laurent Mortier, Stéphane Dalle, Olivier Dereure, Sophie Dalac

EClinicalMedicine· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis